Robert Kerbel
MD
Senior Scientist
👥Biography 个人简介
Robert Kerbel at Sunnybrook is a leading cancer research scientist who developed the concept of metronomic chemotherapy — frequent low-dose chemotherapy designed to have anti-angiogenic activity by continuously targeting dividing endothelial cells while avoiding the toxicities of maximum tolerated dose regimens. He has conducted extensive preclinical studies of bevacizumab combinations and contributed to understanding anti-angiogenic drug resistance.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Robert Kerbel 的研究动态
Follow Robert Kerbel's research updates
留下邮箱，当我们发布与 Robert Kerbel（Sunnybrook Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment